A multicenter prospective study to assess the impact of physician's reinforcement on the subject's compliance and persistence on treatment using feedback on bone markers in previously undiagnosed postmenopausal osteoporotic women treated with risedronate [risedronic acid].
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2006
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms IMPACT
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 14 Sep 2006 New trial record.